Doubled my position in RGBP at $0.03285.
Figured since I was net free already, it's not a huge risk to double down.
Figured since I was net free already, it's not a huge risk to double down.
johnnyblaze36 said:Update: I kind of hate this stock.johnnyblaze36 said:I'm in it at .23 and it was down 41% today with a close of .13Tyrone_The_Tuna said:
ENZC, what are your thought?
I still like the stock but today was brutal.
Quote:
Item 1.01 Entry into a Material Definitive Agreement
On December 16, 2019 Zander Therapeutics, Inc. ("Zander"), KCL Therapeutics, Inc. ("KCL") and Regen Biopharma, Inc. ("Regen") entered into an agreement ("Agreement") whereby:
1) Zander shall return for cancellation 194,285,714 shares of the Series A Preferred stock of Regen ("Conversion Shares") acquired by Zander through conversion of $340,000 of principal indebtedness of a $350,000 convertible note payable issued by Regen to Zander. Subsequent to this event the principal amount due to Zander by Regen pursuant to the Convertible Note shall be $350,000 which shall be applied pursuant to the Agreement.
2) A $35,000 one time charge due to Zander by Regen ("One Time Charge") shall be applied pursuant to the Agreement.
3) $75,900 of principal indebtedness due to Regen by Zander and $4,328 of accrued but unpaid interest due by Regen to Zander shall be applied pursuant to the Agreement.
No actions were taken by any of the parties to enforce the terms of the Agreement.
On April 15, 2021 the Agreement was amended as follows so that the material terms and conditions shall be:
a)
Zander shall not return the Conversion shares for cancellation and the principal indebtedness of the aforementioned convertible note shall not reflect such return
b)
As of December 16, 2019 all principal and accrued interest payable by Regen to Zander on that date resulting from Promissory Notes issued by Regen to Zander shall be credited towards amounts due by Zander pursuant to that agreement, as amended, entered into by and between Zander and Regen on June 23, 2015 ("License Agreement") whereby Regen granted to Zander an exclusive worldwide right and license for the development and commercialization of certain intellectual property controlled by Regen for non-human veterinary therapeutic use for a term of fifteen years and that License Assignment And Consent agreement entered into by and between Regen, KCL and Zander on December 17, 2018 whereby Regen transferred and assigned to KCL all rights, duties, and obligations of Regen under the License Agreement and KCL agreed to assume such duties and obligations thereunder and be bound to the terms of the License Agreement with respect thereto.
shalackin said:
Why can't I find these on Robinhood?
Brian Earl Spilner said:
Ugh. Dare I buy more RGBP? Down to $0.21.